Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Objectives to evaluate the activity of Erlotinib in prostate cancer patients who are hormone
refractory and androgen independent and have not been exposed to chemotherapy.